Advertisement.

RLYB Projected Dividend Yield

Rallybio Corp ( NASDAQ : RLYB )

Rallybio Corporation is a clinical-stage biotech company focused on developing therapies for severe and rare diseases. Their pipeline targets unmet medical needs in maternal fetal health, complement dysregulation, hematology, and metabolic disorders. They have two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), and RLYB116, a complement component 5 (C5) inhibitor for treating complement dysregulation diseases. Other candidates include RLYB114, a C5-targeted molecule for ophthalmic diseases, RLYB331 for severe anemia, and the ENPP1 program.

21 YEAR PERFORMANCE RESULTS

RLYB Dividend History Detail
RLYB Dividend News
RLYB Competitors News

# of Shares: 0

Closing Price: 0.25

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000